Q2 EPS Forecast for Jasper Therapeutics Increased by Analyst

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities research analysts at HC Wainwright increased their Q2 2025 earnings per share estimates for shares of Jasper Therapeutics in a research report issued to clients and investors on Wednesday, July 9th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($1.48) per share for the quarter, up from their prior estimate of ($1.53). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics' Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($5.29) EPS, FY2026 earnings at ($5.95) EPS, FY2027 earnings at ($7.07) EPS, FY2028 earnings at ($8.08) EPS and FY2029 earnings at ($9.25) EPS.

JSPR has been the subject of several other reports. Oppenheimer cut their target price on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. JMP Securities cut their target price on shares of Jasper Therapeutics from $70.00 to $12.00 and set a "market outperform" rating for the company in a research note on Tuesday, July 8th. William Blair reiterated a "market perform" rating on shares of Jasper Therapeutics in a research note on Monday, July 7th. Royal Bank Of Canada downgraded shares of Jasper Therapeutics from an "outperform" rating to a "sector perform" rating and set a $5.00 price objective for the company. in a research report on Tuesday, July 8th. Finally, Cantor Fitzgerald downgraded shares of Jasper Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, July 7th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $29.75.

Jasper Therapeutics Trading Down 1.1%

Shares of NASDAQ JSPR traded down $0.04 during mid-day trading on Monday, hitting $3.47. The company had a trading volume of 410,794 shares, compared to its average volume of 549,084. Jasper Therapeutics has a one year low of $2.27 and a one year high of $26.05. The company has a market capitalization of $52.13 million, a PE ratio of -0.66 and a beta of 2.69. The firm has a 50-day simple moving average of $5.17 and a two-hundred day simple moving average of $6.11.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new stake in shares of Jasper Therapeutics during the first quarter worth $46,000. Corton Capital Inc. acquired a new position in shares of Jasper Therapeutics during the first quarter valued at about $113,000. Wells Fargo & Company MN raised its holdings in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock valued at $159,000 after purchasing an additional 3,828 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Jasper Therapeutics during the fourth quarter worth about $223,000. Finally, Tema Etfs LLC bought a new stake in shares of Jasper Therapeutics during the fourth quarter worth about $266,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.